YARTEMLEA just cleared the commercial hurdle Omeros needed most

The launch ramp materially exceeded the standing expectation. YARTEMLEA generated $32.2 million of gross revenue and $28.5 million of net revenue in its first full commercial quarter, up from $11.1 million and $9.9 million, respectively, in Q1 (Financial Highlights). That net revenue is well above the published quarterly revenue expectation of roughly $12.6 million-$13.0 million, although the comparison is not perfectly clean because the filing highlights product net revenue rather than a consolidated GAAP revenue line.

Underlying profitability improved, not just the headline accounting result. Omeros reported $0.1 million of operating income versus a $17.4 million operating loss in Q1, while research and development plus selling, general and administrative expense rose only modestly to $27.7 million from $26.7 million (Operating Results). The adjusted result excludes a $11.5 million non-cash gain tied mainly to the convertible-note derivative, so the quarter's move into adjusted profitability was not simply created by that accounting item (Financial Highlights).

The capital-structure cleanup helps, but it was not the quarter's surprise. Omeros completed the previously announced repurchase of $30.5 million of 2029 Notes for $60.2 million, reducing remaining principal to approximately $40.3 million, potential conversion shares from 11.4 million to 6.5 million, and future interest payments by $8.6 million (2029 Notes Repurchase). The company also repurchased roughly 0.5 million shares for $5.7 million at an average $11.70 per share (Share Repurchase Program). These actions reduce future dilution and interest burden, but the agreements were entered into in June and July; completion is more confirmation than a fresh surprise.

The European setback remains the main offset, but it predates this filing. CHMP issued a negative opinion on narsoplimab in June, and Omeros has requested re-examination with an external expert group reviewing the evidence (Regulatory Update). That risk was already public before the August 12 results, so it does not erase the commercial beat; it does cap how much of the launch momentum can currently be extrapolated internationally.

Net read: a clear earnings beat driven by stronger-than-expected U.S. adoption. The key change is that YARTEMLEA moved from an early launch experiment to a product producing meaningful revenue and near-term operating breakeven, while permanent J-code coverage is already active and NTAP reimbursement begins October 1, 2026 (Commercial Update). The filing does not provide formal revenue guidance, so the next test is whether this pace holds after the initial launch ramp and reimbursement support takes effect.